PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Pediatric Obesity

Drugs in development · updated 30 October 2026

Pediatric Obesity: drugs in development

As of 30 October 2026 there are 12 active clinical trials (recruiting or ongoing, phases I–III) on 11 drugs for pediatric Obesity. 2 are experimental, that is not yet approved in the United States.

12Active trials
2Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
GenisteinBIO 300I–II1NCT07033767
Efsubaglutide AlfaI1NCT07693426

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
SemaglutideWegovy, RybelsusIII3NCT06934655
CholecalciferolIII1NCT03516968
ExenatideByetta®, Bydureon®III1NCT04520490
MetforminRiomet Er®, Glumetza®III1NCT04578652
PhentermineSuprenza®, Fastin®II2NCT07282340
MidazolamMidazolam Hydrochloride (Autoinjector)®, Midazolam In 0.8% Sodium Chloride®II1NCT06835101
Oxytocin nasal sprayOxytocin 10 Usp Units In Dextrose 5%®, Oxytocin 5 Usp Units In Dextrose 5%®II1NCT04551482
TirzepatideZepbound, MounjaroI1NCT06575738
TopiramateEprontia®, Qudexy Xr®Early I1NCT04881799

Sorted by most advanced phase and number of active trials.

All 11 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D063766 “Pediatric Obesity”.

ItalianoFrançaisDeutsch